

blood

Prepublished online Aug 19, 2008;
doi:10.1182/blood-2008-04-150854

Thalidomide and rituximab in Waldenstrom's macroglobulinemia

Steven P. Treon, Jacob D Soumerai, Andrew R. Branagan, Zachary R. Hunter, Christopher J. Patterson, Leukothea Ioakimidis, Frederick M. Briccetti, Mark Pasmantier, Harvey Zimble, Robert B. Cooper, Maria Moore, John Hill, II, Alan Rauch, Lawrence Garbo, Luis Chu, Cynthia Chua, Stephen H. Nantel, David R. Lovett, Hans Boedeker, Henry Sonneborn, John Howard, Paul Musto, Bryan T. Ciccarelli, Evdoxia Hatjiharissi and Kenneth C. Anderson

Information about reproducing this article in parts or in its entirety may be found online at:
http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests

Information about ordering reprints may be found online at:
<http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl>



Thalidomide and Rituximab in Waldenstrom's macroglobulinemia.

Steven P. Treon^{1,2}, Jacob D. Soumerai¹, Andrew R. Branagan¹, Zachary R. Hunter¹, Christopher J. Patterson¹, Leukothea Ioakimidis¹, Frederick M. Briccetti³, Mark Pasmantier⁴, Harvey Zimble⁵, Robert B. Cooper⁶, Maria Moore⁷, John Hill II⁸, Alan Rauch⁹, Lawrence Garbo⁹, Luis Chu¹⁰, Cynthia Chua¹¹, Stephen H. Nantel¹², David R. Lovett¹³, Hans Boedeker¹⁴, Henry Sonneborn¹⁵, John Howard¹⁶, Paul Musto¹⁷, Bryan T. Ciccarelli¹, Evdoxia Hatjiharissi^{1,2}, Kenneth C. Anderson^{2,18}.

¹Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, ²Harvard Medical School, Boston MA USA; ³New Hampshire Hematology Oncology, Concord New Hampshire, USA; ⁴New York Presbyterian Hospital, Weill Medical College, New York, NY, USA; ⁵Berkshire Hematology Oncology, Pittsfield MA, USA; ⁶Praxair Cancer Center, Danbury Hospital, Danbury CT, USA; ⁷Park Ridge Hospital, Hendersonville NC, USA; ⁸Hendersonville Hematology Oncology, Hendersonville NC, USA; ⁹New York Oncology Hematology, Albany NY, USA; ¹⁰Florida Cancer Specialists, Sarasota FL, USA; ¹¹Oncology Hematology Care, Cincinnati OH, USA; ¹²British Columbia Cancer Agency, Vancouver General Hospital, Vancouver BC, Canada; ¹³Cape Cod Hospital, Hyannis MA, USA; ¹⁴Bridgton Hospital, Bridgton ME, USA; ¹⁵Seacoast Cancer Center, Portsmouth NH, USA; ¹⁶Virginia Oncology Associates, Norfolk VA, USA; ¹⁷Commonwealth Hematology Oncology, Quincy MA, USA; ¹⁸Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston MA USA.

Corresponding author:

Steven P. Treon M.D., M.A., Ph.D.

Dana Farber Cancer Institute

M547, 44 Binney Street

Boston MA 02115 USA

Tel: (617) 632-2681

Fax: (617) 632-4862

Email: steven_treon@dfci.harvard.edu

Abstract

Thalidomide enhances rituximab-mediated antibody dependent cell mediated cytotoxicity. We therefore conducted a phase II study using thalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naïve to either agent. Intended therapy consisted of daily thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks), and rituximab (375 mg/m²/week) dosed on weeks 2-5, 13-16. Twenty-five patients were enrolled, 20 of whom were untreated. Responses were as follows: CR (n=1); PR (n=15); MR (n=2), for an overall and a major response rate of 72% and 64%, respectively, on an intent to treat basis. Median serum IgM decreased from 3,670 to 1,590 mg/dL (p<0.001), while median hematocrit rose from 33.0% to 37.6% (p=0.004) at best response. The median time to progression for responders was 38 months. Peripheral neuropathy to thalidomide was the most common adverse event. Among 11 patients experiencing grade ≥ 2 neuropathy, 10 resolved to \leq grade 1 at a median of 6.7 months. Thalidomide in combination with rituximab is active and produces long- term responses in WM. Lower doses of thalidomide (i.e. \leq 200 mg per day) should be considered given the high frequency of treatment related neuropathy in this patient population. This trial is registered at ClinicalTrials.gov under identifier NCT00142116.

Introduction

Monoclonal antibodies have been successfully used to treat patients with B-cell malignancies, including Waldenstrom's macroglobulinemia (WM). Most of these efforts have focused on the use of rituximab, a chimeric human IgG₁ monoclonal antibody which targets CD20 which is widely expressed in WM^{1,2}. Studies employing standard dose rituximab therapy have demonstrated activity in WM, with overall response rates of 27-35% and median durations of response from 8 to 27+ months²⁻⁷. More recently, the use of extended schedule rituximab has been evaluated wherein patients received 8 infusions of rituximab (375 mg/m²/week) at weeks 1-4 and 12-16. Overall response rates of 44-48% were observed in these studies, with median durations of response from 16+ to 29+ months^{8,9}. Among WM patients receiving rituximab as monotherapy, lower response rates have been observed in those patients with high serum IgM (>6,000 mg/dL) and beta-2 microglobulin (B₂M) (>3.0 mg/L) levels, as well as homozygous expression of phenylalanine at amino acid position 158 on CD16 (FcγRIIIA-158)⁸⁻¹⁰.

Studies combining rituximab with chemotherapy have also been explored in WM¹¹. The combination of nucleoside analogues plus rituximab has yielded major response rates of 70-90%¹²⁻¹⁵, whilst the combinations of CHOP-R (cyclophosphamide, adriamycin, vincristine, prednisone, rituximab) or DC-R (dexamethasone, cyclophosphamide,

rituximab) have resulted in response rates of 80-90%¹⁶⁻¹⁸. Median time to progression in excess of 3 years has been reported with these combinations. Whilst the above combinations have produced more impressive responses, greater toxicity has also been reported in WM patients, with the use of nucleoside analogues causing prolonged neutropenia, stem cell damage, disease transformation, and secondary myelodysplasia/acute leukemia^{11,12,19}.

In an effort to augment monoclonal antibody responses in WM patients whilst averting short and long term chemotherapy-induced toxicities, we have sought the development of immunomodulatory agents for combination therapy with rituximab. Thalidomide is an immunomodulatory agent which induces the elaboration of immunostimulatory cytokines, including interleukin-2 and interferon- γ ²⁰. Importantly, thalidomide induces the expansion of natural killer (NK) cells which are important effectors of *in vivo* rituximab activity, as well as increased antibody dependent cell mediated cytotoxicity (ADCC) induced by rituximab²⁰⁻²⁴. As monotherapy, thalidomide has modest activity in WM patients, producing response rates of 25%, whilst the combination of thalidomide plus steroids and/or clarithromycin produces response rates of 40%²⁵⁻²⁷. In view of these considerations, we carried out a phase II study of thalidomide and rituximab and here present outcome and long term follow-up.

Patients and Methods

Patients with a clinicopathological diagnosis of WM²⁸, who were naïve to rituximab and thalidomide, who had CD20 positive disease as determined by previous bone marrow immunohistochemistry or flow cytometry, and who required therapy based on consensus guidelines²⁹ were eligible for this study. A monoclonal IgM protein, a minimum IgM level ≥ 2 times the upper limit of normal, a baseline platelet count of $\geq 25,000/\mu\text{L}$, an absolute neutrophil count of $\geq 500/\mu\text{L}$, a serum creatinine of < 2.5 mg/dL (unless nephropathy was attributable to their WM), a serum total bilirubin and SGOT of < 2.5 times the upper limit of normal, and an ECOG performance status of 0-2 were required for entry. No chemotherapy, steroid therapy, or radiation therapy within 30 days of study entry was permitted. Patients who were pregnant or lactating, had serious co-morbid disease, had any uncontrolled bacterial, fungal or viral infection, or an active second malignancy were not eligible. All men and women of reproductive potential were required to agree to use an acceptable method of birth control before, and during treatment, as well as for six months after completion of study treatment, and be willing to comply with the FDA-mandated S.T.E.P.S. ® program.

All patients provided informed written consent in accordance with the Declaration of Helsinki, and the Dana Farber/Harvard Cancer Center institutional review board

approved the protocol. Intended therapy consisted of thalidomide administered at a starting dose of 200 mg by mouth each day for 2 weeks, and then escalated to 400 mg by mouth each day for a total treatment period of 52 weeks. Thalidomide was held for each occurrence of grade ≥ 2 non-hematological and/or grade ≥ 3 hematological toxicity, and dose restart at 50% of previous dose was permitted to 50 mg daily when toxicities resolved to $<$ grade 2 for non-hematological or $<$ grade 3 for hematological toxicities, respectively. Rituximab was administered at 375 mg/m^2 once weekly during weeks 2-5 and weeks 13-16, for a total of 8 infusions. Patients who did not tolerate the first cycle (4 infusions) of rituximab therapy were removed from the study and not replaced. Twenty-five patients were enrolled in this study, which utilized a Simon Two-Stage design. Using 80% power and alpha set at 0.05, eleven patients were to be included in the first stage of the two-stage design to test the null hypothesis that the probability of response is $\leq 50\%$ versus the alternative that probability of response $\geq 75\%$. For the first stage, after Rituximab plus Thalidomide is administered to 11 patients, the study would have been terminated if 6 or fewer patients respond. If 7 or more patients responded in the first stage of the trial, an additional 14 patients were to be enrolled and treated during stage II. If, after study completion, the total number responding is greater than 16, the null hypothesis that Rituximab plus Thalidomide treatment produces a response rate less than 50% will be rejected.

Response determination

A baseline evaluation was obtained for enrollment within 30 days prior to initiation of therapy. Patients underwent re-staging studies at 3, 6, and 12 months; and thereafter every 3 months until progression of disease. As part of their response evaluation, all patients underwent history and physical exam; laboratory studies consisting of a complete blood count and differential, serum IgM levels, beta 2 microglobulin (B₂M) levels; and a bone marrow biopsy and aspiration. Response determinations were made using modified consensus panel criteria from the Third International Workshop on WM^{11,30}, and response rates determined on an evaluable basis. A complete response was defined as having resolution of all symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly. Patients achieving a major response and a minor response were defined as achieving a $\geq 50\%$ and $\geq 25\%$ reduction in serum IgM levels, respectively. Patients with stable disease were defined as having $< 25\%$ change in serum IgM levels, in the absence of new or increasing adenopathy or splenomegaly and/or other progressive signs or symptoms of WM. Progressive disease was defined as occurring when a greater than 25% increase in serum IgM level occurred from the lowest attained response value or progression of clinically significant disease-related symptom(s). Time to disease progression (TTP) was calculated from the start of therapy using the Kaplan Meier method.

Analysis of peripheral blood effector cells and Fc γ RIIIA polymorphisms

Serial changes in the absolute levels of peripheral blood effector cells and determination of Fc γ RIIIA-158 polymorphisms were performed as previously described^{10,18}.

Statistical analysis

Comparison of pre- and post-treatment parameters was performed using a two-tailed students t-test on Microsoft Excel™ software. The impact of FcγRIIIA-158 polymorphisms, serum IgM, and B₂M levels on clinical responses was assessed by two-tailed Fisher's exact test (VassarStats). A p-value ≤ 0.05 was deemed to be significant for the above studies.

Results

Patient and disease characteristics

The clinical features of the 25 patients enrolled in this study are summarized in **Table 1**. Of the 25 patients enrolled on study, 20 were previously untreated. Of the 5 previously treated patients, 4 (16%) and 1 (4%) of patients demonstrated relapsed disease or disease refractory to their prior therapy, respectively. Six (24%) of the 25 patients were documented by clinical history and/or examination to have grade 1 sensory neuropathy attributable to their WM at baseline. Anti-myelin associated glycoprotein (MAG) and anti-ganglioside M1 (GM1) antibody studies were obtained on these patients, of whom only one patient was positive for the anti-MAG antibody. The median cumulative dose of thalidomide administered for the intended 52 week treatment period among all enrolled patients was 19,950 mg (range 2,100 to 96,000 mg). Twenty-one and two patients completed 8 and 4 infusions of rituximab therapy, respectively, and therefore were evaluable for response. Both unevaluable patients died prior to completing the first 4 weeks of rituximab therapy due to events deemed unrelated to protocol therapy: (1) complications associated with chronic obstructive pulmonary disease; and (2) autoimmune myopathy and cardiomyopathy. The circumstances of both deaths on study were reviewed by the Drug and Safety Monitoring Board (DSMB), which deemed the events to be unrelated to protocol therapy.

Clinical response to therapy

The individual changes in serum IgM levels at best response for all evaluable patients are shown in **Figure 1**. Median serum IgM levels for all evaluable patients declined from 3,670 mg/dL (range 924-8,610 mg/dL) to 1,590 mg/dL (range 36-5,230 mg/dL) at best response ($p=3.9 \times 10^{-5}$). Pre-therapy, 18/23 (78.3%) patients demonstrated a serum IgM level $\geq 3,000$ mg/dL; at best response, only 6/23 (26.1%) cases had an IgM level $\geq 3,000$ mg/dL. On an intent to treat basis, 18 (72%) patients demonstrated at least a minor response as their best response. Of these patients, 16 (64%) patients achieved a major response, and 2 (8%) patients achieved a minor response. One complete remission was observed among major responders. Sixteen of 20 (80%) of the untreated patients demonstrated a response (including 14 major responders), whereas among previously treated patients, 2/5 (40%) responded (both major responders) ($p=0.11$ by Fisher's Exact T-Test). Improvements in baseline WM related sensory neuropathy were observed in 3/6 patients, including resolution in 2 patients, whereas in one patient the sensory neuropathy worsened. For responding patients, the median time to best response was 18.9 (range 3.8-41.4) months, and the median time for a 25% reduction in serum IgM among responders was 4.7 (range 0.7-24.0) months. Among major responders, the median time to achieving a 50% reduction in serum IgM was 7.9 (range 2.8-21.8) months, which was in line with our previous experience with extended rituximab monotherapy⁸.

Time to progression

The median time to progression for all evaluable patients was 34.8 (range 1.0-49.1) months (**Figure 2**). With a median follow-up of 47.1 months, 10 of the 18 responding patients have progressed. The median time to progression for all responding patients was 38.7 (range 10.3-49.1) months (**Figure 2**). Among untreated patients, the median TTP for untreated patients was 36.04 (range 2.5-49.1) months, whereas among previously treated patients the median TTP was 15.25 (range 1-45.8) months ($p=0.36$).

Changes in hematological parameters

Pre-therapy, 6 (26.1%) and 2 (8.7%) of 23 evaluable patients demonstrated a hematocrit of $\leq 30\%$ and a platelet count of $\leq 100,000/\mu\text{L}$, respectively. Following therapy, and at best response, 1 (4.3%) and none of the 23 evaluable patients demonstrated a hematocrit of $\leq 30\%$ and a platelet count of $\leq 100,000/\mu\text{L}$, respectively. A significant increase in the median hematocrit was noted for the 23 evaluable patients, from 33.0% (range 23.6-42.6%) before to 37.6% (range 29.3-44.3%) following therapy ($p=0.004$). Pre- and post-therapy median platelet counts remained unaffected by therapy ($p=0.73$).

Toxicities

Dose reduction of thalidomide occurred in all patients and led to premature discontinuation in 14 patients. Discontinuation of thalidomide in these patients occurred at a median of 4.1 (range 1.2-10.4) months. Grade ≥ 2 toxicities were as follows:

peripheral neuropathy (44%); somnolence (12%); confusion (12%); rash (8%); tremors (8%); bradycardia (8%); and palpitations (4%). Seven (28%), 4 (16%) and 4 (16%) experienced grade 3, 2 and 1 peripheral neuropathy, respectively. Among the 11 patients experiencing a \geq grade 2 peripheral neuropathy, neuropathies were first reported at a median of 6.3 (range 0.64-11.8) months following initiation of thalidomide. Resolution to \leq grade 1 occurred in 10/11 (91%) patients at a median time of 5.3 (range 1-22.5) months following onset of the neuropathy; complete resolution occurred in 7/11 (63.6%) patients at a median time of 8.8 (2.3-43.7) months. Development of thalidomide related neuropathy occurred in 3/6 patients, (2 grade I, one grade III) which was on par with that experienced with non-WM connected neuropathy patients.

Paradoxical increases in serum IgM levels

Abrupt and paradoxical increases in serum IgM levels have been reported with the use of rituximab in patients with WM which can aggravate hyperviscosity and contribute to hyperviscosity-related symptoms^{7,30,31}. For this reason, plasmapheresis was strongly encouraged for patients who had a pre-therapy serum viscosity of 3.5 CP or greater. Six patients underwent pre-therapy plasmapheresis. Of the 17 patients who did not require prophylactic plasmapheresis prior to the first 4 infusions of rituximab, an increase in serum IgM was observed in 9/17 (52.9%) patients, with a \geq 25% increase in serum IgM in 5/17 (29.4%) patients. Of the 21 patients receiving the second 4-week course of rituximab infusions, one patient required prophylactic plasmapheresis. Of 20 patients who did not require prophylactic plasmapheresis prior to the second course of rituximab,

an increase in serum IgM was observed in 7/20 (35%) patients, with a $\geq 25\%$ increase in serum IgM occurring in only one of 20 (5%) patients.

Effector cell and humoral immunity studies

Pre-therapy, and at months 3 and 6 post therapy, peripheral blood effector cell and uninvolved immunoglobulin studies were assessed for 16 patients. Following 3 and 6 months of therapy, the absolute median levels of total T cells (CD3⁺), natural killer cells (CD16⁺CD56⁺), helper T cells (CD4⁺), and cytotoxic T cells (CD8⁺) remained unaffected, and no correlation was observed with response. Median serum IgA and IgG levels also remained unaffected at month 3, but modestly declined by month 6 with IgA decreasing from 24 to 20 mg/dL (p=0.015) and IgG decreasing from 388 to 348 mg/dL (p=0.012).

Impact of FcγRIIIA-158 polymorphisms, serum IgM and B₂M levels on patient responses.

The overall response rate and time to progression for patients treated with thalidomide and rituximab were determined based on their predicted amino acid polymorphisms in FcγRIIIA-158, which have been shown to be highly predictive of rituximab response in patients with WM¹⁰. The overall response rates were 5/7 (71%) for patients with FcγRIIIA-158 F/F and 13/16 (81%) for FcγRIIIA-158 V/V or V/F (p=1.0). Time to progression for patients with FcγRIIIA-158 F/F and FcγRIIIA-158 V/V or V/F were 32.1 and 37.3 months, respectively (p=0.95). We next analyzed the impact of baseline serum IgM levels using the cutoff of 6,000 mg/dL, which in previous studies served as a determinant for rituximab response in WM. The overall response rate for patients whose IgM was ≥6,000 mg/dL and <6,000 mg/dL were 4/6 (68%) and 14/18 (78%), respectively (p=1.0). Time to progression for patients with patients with ≥6,000 mg/dL and <6,000

mg/dL was 44.4 and 25.0 months, respectively ($p=0.47$). Lastly, we analyzed the impact of B₂M levels on response parameters, given the prognostic significance of this variable in predicting overall survival in WM. Eight of 9 (89%) and 10/14 (71%) patients with a B₂M level of ≥ 3 g/dL and < 3 g/dL, respectively, responded to therapy ($p=0.61$). Time to progression between these subgroups did not differ significantly at 37.6 and 24.1 months, respectively ($p=0.32$).

Discussion

Although CD20 is expressed on malignant cells from nearly all patients with WM, responses to rituximab are seen in only about half of treated patients, even with the use of extended dose schedules. Tumor-related variables including antigen loss, expression of complement resistance antigens, and large tumor burden do not appear to account for the heterogeneity in response to rituximab for patients with WM^{1,2,7,8}. Moreover, we previously reported saturating levels of rituximab on WM cells in patients who had received therapy many months earlier, suggesting that patient-related factors might also account for differential responses to rituximab in WM³³. The possibility that patient-related differences, particularly those effecting ADCC function, might account for variable responses to rituximab in WM was further suggested by studies which correlated NK cell levels, as well as polymorphisms in position 158 of the FcγRIIIA receptor, to rituximab response in indolent NHL including WM^{10,21-23,34}. Given these considerations, we focused our efforts on enhancing rituximab efficacy using agents which augment ADCC activity. In our preclinical studies, thalidomide and its analogue lenalidomide enhanced ADCC activity to rituximab, as well as the CD40 directed SGN-40 monoclonal antibody²⁴. Moreover, in patients receiving thalidomide, increases were noted in circulating NK cells which is particularly important given their prominence as key effectors in patients treated with rituximab. Here, we carried out a clinical trial examining the activity of combination thalidomide and rituximab.

The results of this study demonstrate a high overall (72%) and major response rate (64%) to combination thalidomide and rituximab therapy in WM patients. These results appear to be better than the major response rate reported with either rituximab (40-44%) or thalidomide (25%) monotherapy. Importantly, the responses in this study were durable and in excess of 3 years. The overall response rate and duration of response for thalidomide and rituximab appear on par with other active cytotoxic agent combination therapies employed in WM. Hence, the use of thalidomide and rituximab appears quite appealing as an alternative upfront therapy in WM, given the avoidance of cytotoxic chemotherapy and its stem cell sparing approach.

An important observation in this study was the dose limiting toxicities including neuropathies which necessitated reduction/and or discontinuation of thalidomide in most patients. The dose and schedule of thalidomide should therefore be the subject of further investigation, since lower start doses (≤ 200 mg daily), altered delivery schedule (i.e. 5 days per week), and more prolonged treatment beyond one year may yield more optimal results. It is interesting, however, that several important predictors of rituximab response (Fc γ RIIIa-158 polymorphism status, serum IgM and B₂M levels) were negated in this study with the combination of thalidomide and rituximab. Further studies in larger patient cohorts will be required to confirm these findings since the patient numbers in this series may have contributed to the lack of significance for these variables.

The combination of thalidomide and rituximab did not appear to negate the paradoxical increases in serum IgM levels observed with the use of rituximab in patients with WM. In

this study, we observed that 30% of patients who were not pheresed prior to initiation of the first course of rituximab treatment had a $\geq 25\%$ increase in serum IgM levels, which is on par with that previously reported by us and others^{7,31,32}. Importantly, however, only 5% of the patients receiving the second course of rituximab had a spike of $\geq 25\%$ in serum IgM levels which may reflect the interim response to therapy for many patients. Therefore, close monitoring of serum IgM levels, and symptomatic hyperviscosity should be maintained in patients treated with thalidomide and rituximab, and empiric plasmapheresis considered for patients with elevated serum IgM levels. Accordingly, the use of thalidomide plus rituximab should not be used in patients in whom a rapid decrease in serum IgM levels is required. In such patients other options can be considered, including the use of cytotoxic agent or bortezomib based therapy³⁵.

Lastly, the use of the thalidomide analogue lenalidomide has become increasingly adopted given its higher response rates and fewer non-hematological toxicities in patients with multiple myeloma, as well as other B-cell disorders. We explored its use in combination with rituximab and observed higher ADCC activity in preliminary studies²⁴. However, its use in WM patients appears to be problematic due to the development of acute non-hemolytic anemia, signifying potential idiopathic toxicity for WM patients with this agent. Moreover, the response durations among patients who tolerated combined lenalidomide and rituximab were shorter than in this study^{36,37}. The reason for these discordant findings, particularly since lenalidomide is a more potent immunomodulating agent, remains speculative, but may ultimately involve other activities present in thalidomide but not lenalidomide which benefit WM patients, such as

phosphodiesterase-4 (PDE-4) inhibition³⁸. The investigation of other thalidomide analogues, such as CC-4047, in combination with rituximab would also appear warranted.

In summary, the results of this study demonstrate that thalidomide in combination with rituximab is highly active and produces long-term responses in patients with WM. The use of this combination as upfront therapy in WM patients appears reasonable, particularly in patients who require non-myelosuppressive and stem cell sparing therapy, as well as for patients in whom cytotoxic agents pose undue risks.

Acknowledgements

Supported by the Peter and Helen Bing Fund for Waldenstrom's Macroglobulinemia at the Dana Farber Cancer Institute, the Research Fund for Waldenstrom's at the Dana Farber Cancer Institute, and a National Institutes of Health Career Development Award (K23CA087977-03) to SPT.

Conflict of Interest Disclosure: Drs. Treon and Anderson have received research support, consulting fees, and speaking honoraria from Celgene Inc., and/or Genentech BioOncology Inc.

Authorship

SPT, ARB, ZRH designed and wrote study. JDS, CJP, LI oversaw data collection. EH and BC performed basic science correlation studies. KCA assisted in the study design and implementation. SPT, FMB, MP, HZ, RBC, MM, JH, AR, LG, LC, CC, SHN, DRL, HB, HS, JH, PM treated study patients and provided study data.

References

1. Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC. Treatment of plasma cell dyscrasias by antibody immunotherapy. *Semin Oncol* 1999; 26: 97-106.
2. Treon SP, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, Byrd JC, Schlossman R, Mitsiades N, Mitsiades C, Preffer F, Anderson KC. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic considerations and considerations. *Semin Oncol* 2003; 30: 243-247.
3. Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, Grillo-Lopez AJ. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. *Ann Oncol* 1999; 10: 1525-7.
4. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. *J Clin Oncol* 2000; 18:317-24.
5. Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D,

- Lin B, Kimby E, Anderson KC, Byrd JC: CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's macroglobulinemia. *J Immunotherapy* 2001; 24:272-279.
6. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) *Leuk Lymphoma* 2004; 45:2047-55.
 7. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with rituximab. *J Clin Oncol* 2002; 20:2327-33.
 8. Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR. Extended rituximab therapy in Waldenström's Macroglobulinemia. *Ann Oncol* 2005; 16:132-8.
 9. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia. *Clin Lymphoma* 2005; 5:270-2.

10. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in Fc γ R11A (CD16) receptor expression are associated with clinical responses to Rituximab in Waldenstrom's Macroglobulinemia. *J Clin Oncol* 2005; 23: 474-81.
11. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Blood* 2006; 107:3442-6.
12. Treon SP, Wasi P, Emmanouilides CA, Kimby E, Lister A, Morel P, Frankel S, Preffer F, Kelliher A, Branagan A, Anderson KC. Combination therapy with rituximab and fludarabine is highly active in Waldenstrom's macroglobulinemia. *Blood* 2002; 100:211a.
13. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. *Semin Oncol* 2003; 30:243-7.
14. Tam CS, Wolf MM, Westerman D, et al. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma* 2005; 6:136-9.
15. Hensel M, Villalobos M, Kornacker M, et al. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's

- macroglobulinemia/lymphoplasmacytic lymphoma. *Clin Lymphoma Myeloma* 2005; 6:131-5.
16. Dimopoulos MA, Anagnostopoulos A, Kyrtonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. *J Clin Oncol* 2007; 25:3344-9.
17. Buske C, Dreyling MH, Eimermacher H, Boeck HP, Pfreundschuh M, Metzner B, Fuchs R, Woermann B, Truemper LH, Hess G, Wandt H, Ludwig WD, Kreuser ED, Schimke J, Weh HJ, Schmitz S, Schmiegel W, Unterhalt M, Hiddeman W. Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphoplasmacytoid/ic immunocytoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. *Blood* 2004; 104:162a.
18. Treon SP, Hunter Z, Branagan A. CHOP plus rituximab therapy in Waldenström's Macroglobulinemia. *Clin Lymphoma Myeloma* 2005; 5: 273-7.
19. Leleu XP, Manning R, Soumerai JD, et al. Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's Macroglobulinemia patients treated with nucleoside analogues. *Proc Am Soc Clin Oncol* 2007; 25: 445s.

20. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood* 2001; 98:210-216.
21. Janakiraman N, McLaughlin P, White CA, Maloney DG, Shan D, Wey K, Lopez-Grillo AJ: Rituximab: Correlation between effector cells and clinical activity in NHL. *Blood* 92:337a, 1998.
22. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion: Correlations with clinical response. *Clin Cancer Res* 2004; 10:2253-64.
23. Khan KD, Emmanouilides C, Benson DM, et al. A phase 2 study of rituximab in combination interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. *Clin Cancer Res* 2006; 12:7046-53.
24. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. *Br J Haematol* 2005; 128:192-203.
25. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenström's macroglobulinemia with thalidomide. *J Clin Oncol* 2001; 19:3596-601.

26. Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R, Michaeli J. BLT-D (Biaxin, low dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. *Leuk Lymphoma* 2002; 43: 1777-82.

27. Dimopoulos MA, Tsatalas C, Zomas A, Hamilos G, Panayiotidis P, Margaritis D, Matsouka C, Economopoulos T, Anagnostopoulos A. Treatment of Waldenstrom's macroglobulinemia with single agent thalidomide or with combination of clarithromycin, thalidomide and dexamethasone. *Semin Oncol* 2003; 30: 265-269.

28. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, *et al.* Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. *Semin Oncol* 2003; 30:110–15.

29. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, *et al.* Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. *Semin Oncol* 2003; 30:116–120.

30. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 2006; 6:380-3.
31. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. *Ann Oncol* 2004; 15:1481-3.
32. Ghobrial IM, Fonseca R, Greipp PR, et al: Initial immunoglobulin M "flare" after rituximab therapy in patients with Waldenstrom Macroglobulinemia: An Eastern Cooperative Oncology Group Study. *Cancer* 2004; 101:2593-8.
33. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies. *J Immunotherapy* 2001; 24:263-271.
34. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIA gene. *Blood*. 2002; 99:754-8.
35. Treon SP, Hatjiharissi E, Leleu X, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma* 2007; 5:199-206.

36. Soumerai J, Branagan A, Hunter Z, Patterson C, Hatjiharissi E, Treon SP. Use of the immunomodulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenstrom's macroglobulinemia. *Haematologica* 2007; 92:95.
37. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Chu L, Musto P, Baron AD, Nunnink JC, Kash JJ, Terjanian TO, Hyman PM, Nawfel EL, Sharon DJ, Munshi NC, Anderson KC. Lenalidomide and Rituximab in Waldenstrom's macroglobulinemia. *Clin Cancer Res* 2008 (manuscript in press).
38. Zeldis J, Schafer PH, Bennett BL, Mercurio F, Stirling DI. Potential new therapeutics for Waldenstrom's macroglobulinemia. *Semin Oncol* 2003; 30: 275-81.

	Median	Range
Gender	15 male / 10 female	
Untreated	20/25 (80%)	
Age (years)	62	44-86
BM Involvement (%)	40	5-80
Serum IgM (mg/dL)	3,670	924-8,610
Beta-2-microglobulin (mg/L)	2.6	1.4-8.3
Hematocrit (%)	34.1	23.6-42.6
Platelets (k/ul)	250	93-493
Leukocytes (k/ul)	5.7	2.9-9.4

Table 1. Baseline characteristics for all 25 patients enrolled on study.





Figure 1. Individual changes (%) in serum IgM levels following treatment with thalidomide and rituximab.

A.



B.




Figure 2. Time to progression for (A) all evaluable patients and (B) for those who responded to thalidomide and rituximab. Open circles denote patients who had not progressed at last follow-up.